Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley For Immediate Release Chicago, IL – December 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The labor market cooled in 2025, with unemployment rising to 4.6%, its highest level in several years, and wage growth trending lower

    80% confidence
  • Inflation remained above the Federal Reserve's 2% target in 2025, even as price pressures eased slightly later in the year

    80% confidence
  • NiSource carries a Zacks Rank #2 (Buy)

    80% confidence
  • Strategic alliances and Morgan Stanley's increased focus on less capital market-dependent operations are expected to aid growth, with enhanced capital distribution activities reflecting a solid balance sheet

    80% confidence
  • Invesco pays out a quarterly dividend of 21 cents (84 cents annualized) per share, with a 3.11% yield at the current stock price; IVZ's payout ratio is 44%, with a five-year dividend growth rate of 7%

    80% confidence
  • Real GDP rebounded sharply in the second quarter of 2025, expanding 3.8%, according to the U.S. Bureau of Economic Analysis's third estimate, a 0.5-percentage-point upward revision driven primarily by stronger-than-expected consumer spending

    80% confidence
  • Inflation in 2025 remained above the Federal Reserve's 2% target, even as price pressures eased slightly later in the year

    80% confidence
  • Bunge pays out a quarterly dividend of 70 cents ($2.80 annualized) per share, yielding 3.06% at the current stock price; BG's payout ratio is 37%, with a five-year dividend growth rate of 8.58%

    80% confidence
  • Since 2000, Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year, versus the S&P's +7.7% average gain per year

    80% confidence
  • Invesco currently sports a Zacks Rank #1 (Strong Buy)

    80% confidence
  • Bunge is executing a fundamental transformation anchored by the Viterra merger, expanding global origination, processing scale and logistics efficiency

    80% confidence
  • Morgan Stanley currently has a Zacks Rank #2 (Buy)

    80% confidence
  • NiSource expects to invest $28 billion in 2026-2030 in modernizing infrastructure to enhance the reliability of its operations

    80% confidence
  • Real GDP growth is expected to hover near 2% for 2026, reflecting a slowdown from post-pandemic peaks but signaling continued economic resilience rather than contraction

    80% confidence
  • Morgan Stanley pays out a quarterly dividend of $1.00 ($4.00 annualized) per share, with a 2.26% yield at the current stock price; MS's payout ratio is 41%, with a five-year dividend growth rate of 20.35%

    80% confidence
  • Real GDP growth is expected to hover near 2% for 2026, reflecting a slowdown from post-pandemic peaks but signaling continued economic resilience rather than contraction

    80% confidence
  • Zacks top stock-picking strategies have returned average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to the S&P's +7.7% average gain per year

    80% confidence
  • Invesco's robust AUM balance, diverse product offerings, strong balance sheet and global presence will keep supporting financials, and synergies from acquisitions will keep aiding profitability

    80% confidence
  • Invesco currently sports a Zacks Rank #1 (Strong Buy)

    80% confidence
  • Invesco's robust AUM balance, diverse product offerings, strong balance sheet and global presence will keep supporting financials; synergies from acquisitions will keep aiding profitability

    80% confidence
  • Johnson & Johnson currently has a Zacks Rank #2 (Buy)

    80% confidence
  • Johnson & Johnson pays out a quarterly dividend of $1.30 ($5.20 annualized) per share, with a 2.52% yield at the current stock price; JNJ's payout ratio is 50%, with a five-year dividend growth rate of 5.39%

    80% confidence
  • Real GDP growth for 2025 is projected at about 2%, reflecting steady but below-trend expansion compared with historical averages

    80% confidence
  • Inflation is projected to gradually moderate in 2026, allowing the Federal Reserve greater flexibility to pivot toward a more accommodative policy stance

    80% confidence
  • NiSource pays out a quarterly dividend of 28.7 cents ($1.12 annualized) per share, yielding 2.7% at the current stock price; NI's payout ratio is 60%, with a five-year dividend growth rate of 6.22%

    80% confidence
  • Morgan Stanley currently has a Zacks Rank #2 (Buy)

    80% confidence
  • NiSource is benefiting from consistent investments to strengthen its infrastructure and expects to invest $28 billion in 2026-2030 in modernizing infrastructure

    80% confidence
  • Johnson & Johnson has more than 275 subsidiaries, reflecting an extremely well diversified business

    80% confidence
  • Real GDP rebounded sharply in the second quarter of 2025, expanding 3.8%, according to the U.S. Bureau of Economic Analysis's third estimate, marking a 0.5-percentage-point upward revision driven primarily by stronger-than-expected consumer spending

    80% confidence
  • Johnson & Johnson currently has a Zacks Rank #2 (Buy)

    80% confidence

Data points we hold from this source

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com